Science 20.11.2020

Among the best of these Since the International Track University, Stanford Universi- and the spirit of entrepreneur-
teams is “Youmi Technology” was set up as part of the com- ty, and Massachusetts Institute ship among students. In 1999, it
from South China University petition in 2017, the numbers of of Technology. College stu- was the first university in China
of Technology. In 2015, it won international universities, pro- dents in China are presenting to promote the goal of “inno-
the second place at the first jects and students participating an international business card vation, creation, and entrepre-
“Internet+” Competition with in the event have been increas- of the “Internet+” Competition neurship” in student training.
its leading intelligent digital ing year by year. In 2020, the to their peers across the globe. Through a series of reforms, it
marketing technology. Today, 6th “Internet+” Competition has established a comprehensive
Youmi Technology Co., Ltd., an adds the word “international” South China University of education system for innovation
enterprise founded by the team, to its name for the first time. It Technology (SCUT), which and entrepreneurship. Focusing
has been listed as one of the “Top has attracted more than 6 mil- is the host of this year’s com- on emerging engineering fields,
100 Internet Companies in Chi- lion entrants from China and petition, is a comprehensive, it aims to cultivate talents that
na”. Since the start of the com- abroad. There are 3,291 inter- research-intensive university will shape the future with capa-
petition, more and more Chinese national projects developed by located in Guangzhou, the third bilities of “learning, thinking,
college students have devoted teams from 1,158 universities largest city in China. In 2020, it and acting”. Up till now, there
themselves to entrepreneurship. outside China, among which was ranked within the world’s are nearly 100 listed compa-
Statistics show that 741,000 col- many are f rom the world’s top 200 universities by the Ac- nies founded or led by alumni
lege students started their own best-known universities, such ademic Ranking of World Uni- of SCUT, which is therefore
businesses in 2019, with an in- as University of Oxford, Uni- versities. SCUT has a long tra- known as the “cradle of entre-
crease of 9% compared to 2018. versity of Cambridge, Harvard dition of and rich experience in preneurs”.
fostering abilities of innovation

The finals of the 6th China Center f rom November 17 people from all over the world na, they will set an example of
International College Stu- to 21, 2020. The finals will to join us in this event where innovation and entrepreneur-
dents’ “Internet+” Innova- proceed in both on-site and creativity converges, aspira- ship for the youth worldwide
tion and Entrepreneurship online venues, enabling stu- tions emerge, and cooperative in this new era.
Competition will be held at dents from different countries awareness develops. As young
SCUT’s campus at the Guang- and regions to compete in the talents compete, communi-
zhou Higher Education Mega same arena. We expect young cate, and cooperate in this are-

ADVERTISEMENT

online @sciencecareers.org Assistant Professors
Department of Biological Engineering

The Ragon Institute, together with the Department of Biological Engineering at the Massachusetts Institute of Technology (MIT), in Cambridge, MA is
seeking outstanding scientists for tenured or tenure-track faculty positions to start July 1, 2021 or on a mutually agreed date thereafter. The Institute is
located at the heart of the MGH, MIT and Harvard communities in Kendall Square with state-of-the-art research facilities. The Ragon Institute was officially
established in February 2009 as a joint institute involving faculty from Massachusetts General Hospital (MGH), MIT, and Harvard University. The MIT
Department of Biological Engineering at MIT has a long established presence as a leader in the field especially in the areas of immune engineering and
infectious diseases.

The missions of the Ragon Institute and MIT BE are highly complementary: The Ragon Institute’s ultimate goal is to harness the immune system to prevent
and cure human diseases. MIT BE aims to lead the discipline of biological engineering, fusing engineering with modern molecular-to-’omic biology to
measure, model, manipulate, and make biological systems for powerful new biological technologies. Candidates for this joint position may have research
interests broadly at the interface of these two missions relating to immunology, immunotherapy, and infectious disease. Examples of particular areas of
interest for joint appointment at the Ragon Institute and MIT BE include: systems biology, computational modeling, or machine learning approaches to
studying host-pathogen interactions or the immune system; imaging technologies for macro- to nano-scale structural biology; engineering approaches
toward the understanding or therapeutic modulation of innate or adaptive immunity.

The search is for candidate(s) to be hired at the assistant professor level; however, under special circumstances, a senior faculty appointment with tenure
is possible, commensurate with experience. Applicants must have a Ph.D. and/or M.D. or equivalent degree in Biology and related fields (Biochemistry,
Microbiology, etc.), Computer Science, or Engineering (Biological, Mechanical, Chemical, etc.) by the start of employment, and have a track record of
exceptional achievement in basic or translational research and the potential to develop an outstanding independent research program that supports the
Institute’s ultimate goal of harnessing the immune system to prevent and cure human diseases.

MIT faculty duties include teaching at the undergraduate and/or graduate levels, research, and supervision of student research. The successful candidates
will be provided with a generous start-up package to complement outstanding laboratory and oFce space, as well as access to state-of-the-art core
facilities including advanced flow cytometry, microscopy, BSL-3 facilities and an extensive clinical specimen repository. The successful candidates will be
expected to build and maintain an internationally recognized, extramurally funded research program complemented by substantial support from Institute
funds. The candidates should possess the ability to work collaboratively with other scientists, in addition to the scholarly qualities required to mentor
doctoral students from graduate programs at MIT.

Interested candidates should submit application materials electronically at https://school-of-engineering-faculty-search.mit.edu/mit-ragon. Each
application must include: a curriculum vitae; the names and addresses of three or more references; a strategic statement of research interests; and a
statement of teaching interests. In addition, candidates should provide a statement regarding their views on diversity, inclusion, and belonging, including
past and current contributions as well as their vision and plans for the future in these areas. It is the responsibility of the candidate to arrange for reference
letters to be uploaded at https://faculty-searches.mit.edu/letters/. Please address questions to the search committee chair, Dr. Darrell Irvine
([email protected]). Responses received by December 1, 2020 will be given priority.

With MIT’s strong commitment to diversity in engineering and science education and research, http://web.mit.edu
we especially encourage those who will contribute to our diversity and outreach eUorts to apply.

MIT is an equal employment opportunity employer.

ASSISTANT / ASSOCIATE PROFESSOR myIDP:
A career plan customized
Pharmaceutics for you, by you.

WAYNE STATE UNIVERSITY For your career in science, there’s only one
The Department of Pharmaceutical Sciences, Eugene Applebaum College
of Pharmacy and Health Sciences, invites applications for a 12-month Features in myIDP include:
tenure-track Assistant or Associate Professor position. Applicants are
to have an earned PhD in the pharmaceutical sciences or in a related  Exercises to help you examine your skills, interests,
discipline, or an MD or equivalent degree. Scientists with a record of
high impact research in pharmaceutics at the chemical biology interface and values.
in areas drug discovery, delivery and development, metabolic disease,
neurosciences and oncology will receive preference. The fnalist will  A list of 20 scientifc career paths with a prediction
have or develop a vigorous externally funded research program and
teach effectively in our PhD, MS and PharmD programs. We offer of which ones best ft your skills and interests.
an uncommonly collegial academic culture, competitive start-up and
compensation packages, generous benefts, premiere laboratory facilities Visit the website and start planning today!
and extensive research support. Submit applications via http://jobs.wayne. myIDP.sciencecareers.org
edu under Department H1822-Pharmaceutical Sciences posting #044919.
Further details are available from Dr. Timothy Stemmler tstemmle@med. In partnership with:
wayne.edu or (313) 577-5712.

Wayne State University is a Carnegie Highest Research Activity (R1)
institution and a premier, public, urban research university in midtown
Detroit where students from all backgrounds enjoy a rich, high quality
education. The College is in one of the most dynamic communities
leading city revitalization. The metropolitan area offers a cosmopolitan
environment with rich cultural offerings, strong schools and outstanding
affordable housing in the beautiful Great Lakes region. Our deep-
rooted commitments to excellence, collaboration, integrity, diversity and
inclusion give students exceptional preparation for success in a global
society. We encourage applications from all underrepresented groups
including women and people of color.

Wayne State is an affrmative action/equal opportunity employer. All
qualifed applicants will receive consideration without regard to race,
color, religion, sex, national origin, age, disability, veteran status, or any
other characteristic protected by law. Application review will begin in late
November, 2020. The positions will remain open until flled.

GROUP LEADERS online @sciencecareers.org
Centers of Research Excellence
Ohio State University Comprehensive Cancer Center FACULTY POSITION IN PHARMACOLOGY
Pelotonia Institute for Immuno-Oncology AND CHEMICAL BIOLOGY

The Ohio State University Comprehensive Cancer Center – Arthur Baylor College of Medicine (BCM) is recognized as one of
G. James Cancer Hospital and Richard J. Solove Research Institute the nation’s premier academic health science centers and is
(OSUCCC – James) is seeking candidates for the position of Group known for excellence in education, research, and healthcare
Leader in the Pelotonia Institute for Immuno-Oncology (PIIO). This is and community service. Located in the Texas Medical
an excellent opportunity for a proven leader and innovator with an Center, BCM offers a highly interactive environment and
active and established research program to join the PIIO’s executive a strong infrastructure for research. The Department of
team in accelerating the pace for discovery and translation in immuno- Pharmacology and Chemical Biology is focused on using
oncology (IO). small molecules and biologics to understand and modify
disease-relevant cellular processes. The Department invites
The PIIO is a comprehensive bench-to-bedside research initiative applications from outstanding scientists for a tenure track
focused on developing life-saving cancer immunotherapy breakthroughs position at the Assistant, Associate or Full Professor rank.
at all levels – from prevention to treatment to survivorship. Established
by a pledge of more than $100 million from Pelotonia (pelotonia.org) The successful candidate will possess or develop an
and the OSUCCC - James, the PIIO represents Ohio State University’s independent, funded research program in drug discovery,
commitment to grow the exciting area of immuno-oncology. Led by chemical biology, protein design and engineering or other
founding director and renowned immunologist Zihai Li, MD, PhD, areas broadly relevant to pharmacology. The candidate will
the PIIO builds upon a rich portfolio of active investigator-initiated IO supervise graduate students and postdoctoral fellows and
clinical trials being conducted at the OSUCCC – James. Its external contribute to the educational programs in the Department
advisory board is comprised of multiple world leaders in the feld of IO and College. Candidates should have a Ph.D. and/or M.D.
including Drs. Lisa Butterfeld, Lieping Chen, Carl June, Miriam Merad, degree and postdoctoral experience as well as a strong record
Robert Schreiber, and Cassian Yee (cancer.osu.edu/PIIO). The Institute’s of research accomplishments. Competitive compensation
initiatives include recruiting outstanding researchers; developing frst- and a generous start up package will be provided.
in-class, frst-in-man IO agents; training the next generation of IO
scientists; and fostering high-impact and holistic partnerships. Applicants should submit a curriculum vitae, summary of
research accomplishments, statement of research interests,
The successful candidate will serve as a senior member of the PIIO’s and the names of three references as a single PDF to
leadership team, directing one of the Institute’s four interconnected [email protected]. Review of applications will
Centers of Research Excellence: begin in December 2020, and continue until the position is
filled. Diversity among BCM’s students, trainees, faculty and
• Cancer Immuno-Genomics: a program conducted in partnership staff is a prerequisite to accomplishing BCM’s institutional
with Nationwide Children’s Hospital which involves understanding the mission, and to maintaining the highest standards in training
relationship between cancer genomics and immune evasion and includes for healthcare providers and biomedical scientists, scientific
epigenetics, neo-antigen vaccine, epitope prediction, TCR repertoire innovation, and patient-centered care.
analysis, HLA typing, and CRISPR screening;
• Cell Therapy: where immune cells are collected from a patient’s blood, BCM is committed to ensuring equal opportunity for all
engineered, and returned to that patient to target and eradicate cancer and qualified persons without taking into account race, color,
includes adoptive cell therapy with T cells and natural killer cells; national origin, creed, sex, sexual orientation, ancestry, age,
• Systems Immuno-Oncology: which seeks a better understanding of
cellular systems to create more effcient and effective immunological veteran status or disability unrelated to job requirements.
tools to fght cancer and includes immune regulation, microbiome, NK
and T cell biology, and tumor microenvironment;
• Translational Immuno-Oncology: an area that focuses on transforming
immuno-oncology discoveries into new or improved cancer
treatments applicable at patient bedsides. This team works with the Drug
Development Institute at the OSUCCC – James on developing new drug
therapies.

The successful candidate – while maintaining an independent research
program and obtaining extramural funding – will recruit, retain, and
further develop strong investigators committed to advancing their Center
of Research Excellence; set the strategic vision for growing its Center’s
research initiatives; and develop and enhance collaborative partnerships
both internally and externally. The Group Leader will work closely with
leaders of the PIIO’s Immuno-Informatics (Data Science) Group,
where big data and quantitative science are used to improve immuno-
oncology research and includes machine learning, neo-antigen discovery,
spatial statistics, etc.; and Immune Monitoring and Discovery
Platform, which is backed by a new facility with technology that allows
scientists to get a 360-degree view—down to the single-cell level—of
what happens in the immune system during treatment with immuno-
oncology agents.

Candidates will have access to state-of-the-art laboratory spaces;
cutting-edge core research facilities (Spectrum Flow Cytometry, Time-
of-Flight Mass Cytometry, Multiplex Histology, Single Cell Technology,
GMP Facility for Cell Therapy, Antibody Engineering Facility,
Immuno-Informatics and more); a competitive salary commensurate with
experience, and ample start-up funding.

Applicants must hold advanced degrees such as a MD, DVM, PharmD,
PhD, or MD/PhD. The ideal candidate will have a national and
international reputation in their feld and signifcant independent
research experience with both historical and current federal
funding of research projects as a Principal Investigator. The successful
candidate is expected to maintain an extramurally funded research
program, perform collaborative research with others, participate in
graduate and medical education, and must be board-certifed and meet
medical licensure requirements in Ohio for those also pursuing a
clinical position. The successful candidate will become faculty at the
rank of either Associate Professor or Full Professor. The Ohio State
University is an EOE/AA/M/F/D/V employer.

To Apply: Send cover letter, Curriculum Vitae, 2-3 page description of
current and future research interests, and contact information for three
references to the offce of the director of the PIIO, Zihai Li, MD, PhD,
via Tamra Brooks at [email protected].

LIFE SCIENCE TECHNOLOGIES Produced by the Science/AAAS Custom Publishing Office

new products: immuno-oncology

Optimized Microplates for Affinity Customized CAR-T Constructs
Binding Assays AMS Biotechnology announces a custom chimeric antigen receptor
Porvair Sciences’ medium- and high- T-cell (CAR-T) service. Drawing upon our expertise in monoclonal
bind Krystal microplates set a new antibody development (rabbit and mouse), we can help you
standard for uniform and reproducible design, plan, and execute your CAR-T study, whether you are in
capture of a wide range of biomolecules the preclinical, clinical, or proof-of-concept stage. We can start
ready for affinity binding assays such with a target molecule (Phase I) or antibody (Phase II). Then we
as ELISAs. Manufactured from high-quality crystal polystyrene, construct the single-chain variable fragment (ScFv), transfer it into
these new automation-ready plates are available in a choice of a CAR lentivector of your choice, make lentiviruses, and transduce
ANSI/SLAS standard (96-well and breakable 8-well-strip) formats. activated human (or mouse) T-cells. After the CAR-T cells proliferate,
Offering working volumes up to 320 µL, the plates incorporate a cytotoxicity is measured in a real-time assay, CAR expression is
flat bottom to ensure superb assay detection every time. Designed analyzed, and cytokine production is quantified.
for hydrophobic passive adsorption of lipid-rich large biomolecules AMS Biotechnology
and antigens, including viral antigens, medium-bind Krystal plates For info: 617-945-5033
offer a binding capacity of approximately 100 ng immunoglobulin www.amsbio.com/custom-car-t-development
G (IgG)/cm²–200 ng IgG/cm². Krystal high-bind plates are optimized
for passive adsorption of proteins with different grades of Fluorescent-Labeled Recombinant Proteins
hydrophilicity. Offering a binding capacity of 400 ng IgG/cm²–500 R&D Systems fluorescent-labeled proteins are designed to simplify
ng IgG/cm², the high-bind plates are ideal for immunoassay of detection of a specific chimeric antigen receptor (CAR) on CAR-T
glycoproteins and serum samples. cells. Our fluorescent-labeled recombinant proteins are amine-
Porvair Sciences labeled and rigorously tested to ensure consistent labeling of each
For info: 800-552-3696 lot. The proteins are manufactured with controlled procedures to
w w w.microplates.com / kr y s t al - medium -and - high - bind ensure a consistent fluorescein to protein (F/P) ratio, and quality-
control tested by flow cytometry to evaluate equivalent staining.
T-Cell Activation Assay Kit Using fluorescent-labeled proteins, target cells expressing the
The Agilent Seahorse XF T-cell activation assay offers you improved corresponding CAR can be directly stained and detected by flow
insight into early T-cell activation dynamics with the ability to test cytometry. This method of evaluating CAR expression is highly
modulators in real time. Our new turnkey solution, the Seahorse XF specific, reduces processing time, and eliminates background
Hu T-Cell Activation Assay Kit, provides you with validated reagents staining that may occur by indirect detection of the CAR using an
for consistent results; streamlined workflows with ready-to-use, epitope-tagged target antigen and a fluorophore-labeled secondary
PDL-coated XF microplates; and a convenient data-analysis tool for antibody.
profiling maximum response and area under curve. By measuring R&D Systems
the increase in glycolysis as proton efflux rate, Agilent Seahorse For info: 800-343-7475
technology provides an early kinetic window to interrogate T-cell www.rndsystems.com
activation.
Agilent FFPE and Liquid Biopsy Reference Standards
For info: 800-227-9770 Horizon Discovery Group has added two new sample formats
www.agilent.com to its cell-based OncoSpan reference standards for use in the
development and validation of workflows for cancer diagnostic
Antibody Panels for Immune Checkpoints assays. Horizon’s OncoSpan range now includes formalin-fixed,
Discover our range of hand-picked antibody panels to key immuno- paraffin-embedded (FFPE) and cell-free DNA (cfDNA) formats for
oncology targets, which are designed to save you time and provide mimicking solid tumors and liquid biopsy samples, respectively,
you with easy access to the best selection of clones on the market. in addition to its well-established genomic DNA format. Its cfDNA
Each panel contains a selection of monoclonal antibodies that detect format offers one of the largest number of variants and genes—over
the same protein, increasing your chances of finding a compatible 380 and 152 respectively—of any characterized reference standard,
clone for your assay with just one purchase. We eliminate the need to help standardize liquid biopsy testing. These cell line–derived
for prescreening by narrowing our catalog to the most suitable reference standards closely mimic patient samples and offer an
immunohistochemistry (IHC)-optimized clones and packaging them unlimited, reproducible resource to ensure consistency during the
in an easily accessible kit so you can determine the best antibody for establishment and validation of diagnostic assays. All three formats
your IHC research assay needs. are delivered with batch-specific NGS data, orthogonally validated
abcam by droplet digital PCR, to allow researchers to further validate their
For info: 888-772-2226 analysis pipeline.
www.abcam.com Horizon Discovery Group
For info: 800-235-9880
horizondiscovery.com

Electronically submit your new product description or product literature information! Go to www.sciencemag.org/about/new-products-section for more information.

Newly offered instrumentation, apparatus, and laboratory materials of interest to researchers in all disciplines in academic, industrial, and governmental organizations are featured in this
space. Emphasis is given to purpose, chief characteristics, and availability of products and materials. Endorsement by Science or AAAS of any products or materials mentioned is not
implied. Additional information may be obtained from the manufacturer or supplier.

1000 sciencemag.org/custom-publishing SCIENCE